AVP‐825 Breath‐Powered Intranasal Delivery System Containing 22 mg Sumatriptan Powder vs 100 mg Oral Sumatriptan in the Acute Treatment of Migraines (The COMPASS Study): A Comparative Randomized Clinical Trial Across Multiple Attacks

By  

HEADACHE, Vol. 55, Iss. 5, 2015-05 ,pp. : 621-635

John Wiley & Sons Inc

Access to resources Recommend Favorite

A Randomized, Double‐Blind, Placebo‐Controlled Study of Breath Powered Nasal Delivery of Sumatriptan Powder (AVP‐825) in the Treatment of Acute Migraine (The TARGET Study)

By  

HEADACHE, Vol. 55, Iss. 1, 2015-01 ,pp. : 88-100

John Wiley & Sons Inc

Access to resources Recommend Favorite

Sumatriptan Iontophoretic Transdermal System Reduces Treatment‐Emergent Nausea and Is Effective in Patients With and Without Nausea at Baseline – Results From a Randomized Controlled Trial

By  

HEADACHE, Vol. 17-8748, Iss. 8, 2015-09 ,pp. : 1124-1132

John Wiley & Sons Inc

Access to resources Recommend Favorite

Sumatriptan Iontophoretic Transdermal System Reduces Treatment‐Emergent Nausea and Is Effective in Patients With and Without Nausea at Baseline – Results From a Randomized Controlled Trial

By  

HEADACHE, Vol. 55, Iss. 8, 2015-09 ,pp. : 1124-1132

John Wiley & Sons Inc

Access to resources Recommend Favorite

A Randomized Trial Comparing the Pharmacokinetics, Safety, and Tolerability of DFN‐02, an Intranasal Sumatriptan Spray Containing a Permeation Enhancer, With Intranasal and Subcutaneous Sumatriptan in Healthy Adults

By  

HEADACHE, Vol. 56, Iss. 9, 2016-10 ,pp. : 1455-1465

John Wiley & Sons Inc

Access to resources Recommend Favorite